Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2.
The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders.
In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | May 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 77 |
| CEO | Saurabh Saha |
Contact Details
Address: 1 Ashley Road, 3rd Floor Altrincham, WA14 2DT United Kingdom | |
| Website | centessa.com |
Stock Details
| Ticker Symbol | CNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001847903 |
| CUSIP Number | 152309100 |
| ISIN Number | US1523091007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | Chief Executive Officer and Director |
| John J. Crowley CPA | Chief Financial Officer and Principal Financial and Accounting Officer |
| Tia L. Bush | Chief Technology and Quality Officer |
| Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Karen M. Anderson | Chief People Officer |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Dr. Mario Alberto Accardi Ph.D. | President of the Orexin Program |
| Charlene Stoudt | Senior Vice President of Clinical Development Operations |
| Dr. Stephen J. Kanes M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G | Filing |
| May 6, 2025 | ARS | Filing |
| May 6, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | 144 | Filing |
| Apr 25, 2025 | 144 | Filing |
| Apr 25, 2025 | 144 | Filing |
| Apr 22, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 22, 2025 | 144 | Filing |
| Apr 21, 2025 | 144 | Filing |
| Mar 25, 2025 | 144 | Filing |